Citius Pharmaceuticals reported a modest QoQ revenue uptick in QQ4 2024, but the quarter amplified the company’s ongoing profitability and liquidity challenges. Revenue for QQ4 2024 was $0.156 million, up from $0.053 million in QQ3 2024, while operating losses persisted at -$11.05 million and EBITDA stood at -$10.997 million, translating to an EBITDA margin of -70.5%. Net income was -$10.79 million with an EPS of -$0.0621, underscoring that the business remains in a development-stage phase with no commercialized products generating meaningful topline revenue.
The balance sheet shows a tight liquidity position: cash and cash equivalents of $3.25 million at quarter-end, a current ratio of 0.40, and inventory of $8.27 million against current liabilities of $35.81 million. Intangible assets are substantial at $92.8 million, with goodwill of $9.35 million, yielding a total asset base of roughly $116.65 million. Retained earnings sit deeply negative at -$201.37 million, and total stockholders’ equity stands at ~$70.08 million. Net debt was modestly negative (-$2.99 million), reflecting cash on hand but not offsetting the aggressive annualized cash burn.
Management commentary (where available) focused on the developmental nature of the pipeline and anticipated milestones rather than near-term revenue. In absence of an earnings call transcript, concrete management quotes are not available here; the key takeaway is that CTXR remains pipeline- and milestone-driven, with liquidity and capital formation as the critical near-term constraints. Investors should monitor runway, potential licensing or collaboration deals, and regulatory progress for its five-candidate portfolio.